CAEL-101

Unassigned

New Medicines

Cardiac light-chain (AL) amyloidosis

Information

New molecular entity
Alexion
Alexion

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

A chimeric fibril-reactive monoclonal antibody, intended reduce or eliminate both amyloid γ and κ deposits.
Light chain amyloidosis (AL) is a rare monoclonal plasma cell disorder similar to multiple myeloma, producing fibrils of monoclonal immunoglobulin (Ig) deposited extra-cellularly. Almost any organ can be affected, however cardiac involvement is present at diagnosis in >50% [3]. Annual incidence is about 1 per 100,000 and UK prevalence about 2 per 100,000 [4].
Cardiac light-chain (AL) amyloidosis
Intravenous infusion